Foghorn Therapeutics (FHTX) Return on Sales (2020 - 2025)
Historic Return on Sales for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to 2.02%.
- Foghorn Therapeutics' Return on Sales rose 4300.0% to 2.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.06%, marking a year-over-year increase of 5200.0%. This contributed to the annual value of 3.83% for FY2024, which is 9500.0% down from last year.
- Per Foghorn Therapeutics' latest filing, its Return on Sales stood at 2.02% for Q3 2025, which was up 4300.0% from 2.49% recorded in Q2 2025.
- Foghorn Therapeutics' 5-year Return on Sales high stood at 0.82% for Q3 2023, and its period low was 652.68% during Q3 2021.
- In the last 5 years, Foghorn Therapeutics' Return on Sales had a median value of 5.27% in 2023 and averaged 48.72%.
- In the last 5 years, Foghorn Therapeutics' Return on Sales tumbled by -5482600bps in 2021 and then surged by 6488000bps in 2022.
- Over the past 5 years, Foghorn Therapeutics' Return on Sales (Quarter) stood at 39.98% in 2021, then surged by 83bps to 6.9% in 2022, then soared by 39bps to 4.18% in 2023, then tumbled by -63bps to 6.83% in 2024, then soared by 70bps to 2.02% in 2025.
- Its Return on Sales was 2.02% in Q3 2025, compared to 2.49% in Q2 2025 and 3.4% in Q1 2025.